Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.

Abstract

OBJECTIVES:

An increased risk of drug-related liver injury has been repeatedly reported in individuals infected with hepatitis C virus (HCV) receiving the antiretroviral drug nevirapine. This study was undertaken to assess the differences in the pharmacokinetics of nevirapine between patients with HIV/HCV coinfection and HIV infection that could explain higher rates of hepatotoxicity.

METHODS:

A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected. Advanced liver disease was an exclusion criterion in order to assess the impact of chronic HCV infection alone.

RESULTS:

Comparing the two groups, no difference was observed between minimum and maximum drug levels or total drug exposure in terms of area under the curve.

CONCLUSIONS:

Hepatitis C coinfection does not alter the pharmacokinetics of nevirapine in patients with preserved liver function.

• Authors: Martin Vogel, Norbert Bertram, Jan-Christian Wasmuth, Christoph Wyen, Esther Voigt, Carolynne Schwarze-Zander, Thomas Sudhop, Gerd Fätkenheuer, Jürgen K Rockstroh, Christoph Reichel
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 63 Issue 5 Pg. 988-91 (May 2009) ISSN: 1460-2091 [Electronic] England
• PMID: 19270314 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Nevirapine

Topics

• Adult
• Antiviral Agents (pharmacokinetics, therapeutic use)
• Female
• HIV Infections (complications, drug therapy)
• Hepatitis C, Chronic (complications, drug therapy)
• Humans
• Male
• Middle Aged
• Nevirapine (pharmacokinetics, therapeutic use)
• Serum (chemistry)